Literature DB >> 18289614

Predictive validity of animal pain models? A comparison of the pharmacokinetic-pharmacodynamic relationship for pain drugs in rats and humans.

G T Whiteside1, A Adedoyin, L Leventhal.   

Abstract

A number of previous reviews have very eloquently summarized pain models and endpoints in animals. Many of these reviews also discuss how animal models have enhanced our understanding of pain mechanisms and make forward-looking statements as to our proximity to the development of effective mechanism-based treatments. While a number of reports cite failures of animal pain models to predict efficacy in humans, few have actually analyzed where these models have been successful. This review gives a brief overview of those successes, both backward, providing validation of the models, and forward, predicting clinical efficacy. While the largest dataset is presented on treatments for neuropathic pain, this review also discusses acute and inflammatory pain models. Key to prediction of clinical efficacy is a lack of side effects, which may incorrectly suggest efficacy in animals and an understanding of how pharmacokinetic parameters translate from animals to man. As such, this review focuses on a description of the pharmacokinetic-pharmacodynamic relationship for a number of pain treatments that are effective in both animals and humans. Finally we discuss where and why animal pain models have failed and summarize improvements to pain models that should expand and improve their predictive power.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18289614     DOI: 10.1016/j.neuropharm.2008.01.001

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  40 in total

1.  Do mice have a pain face?

Authors:  Paul A Flecknell
Journal:  Nat Methods       Date:  2010-06       Impact factor: 28.547

2.  Overcoming obstacles to developing new analgesics.

Authors:  Clifford J Woolf
Journal:  Nat Med       Date:  2010-10-14       Impact factor: 53.440

3.  Rationale and methods for assessment of pain-depressed behavior in preclinical assays of pain and analgesia.

Authors:  S Stevens Negus; Edward J Bilsky; Gail Pereira Do Carmo; Glenn W Stevenson
Journal:  Methods Mol Biol       Date:  2010

4.  Novel therapies for the control and prevention of neuropathic pain.

Authors:  Christine N Sang; Gary J Bennett
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

5.  Laboratory environmental factors and pain behavior: the relevance of unknown unknowns to reproducibility and translation.

Authors:  Jeffrey S Mogil
Journal:  Lab Anim (NY)       Date:  2017-03-22       Impact factor: 12.625

6.  Optimised protocol design for the screening of analgesic compounds in neuropathic pain.

Authors:  A Taneja; J Nyberg; M Danhof; O Della Pasqua
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-30       Impact factor: 2.745

7.  Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats.

Authors:  Elke H J Krekels; Marie Angesjö; Ingemo Sjögren; Kristina Angeby Möller; Odd-Geir Berge; Sandra A G Visser
Journal:  Pharm Res       Date:  2011-02-23       Impact factor: 4.200

8.  Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens.

Authors:  Darue A Prieto; Donald J Johann; Bih-Rong Wei; Xiaoying Ye; King C Chan; Dwight V Nissley; R Mark Simpson; Deborah E Citrin; Crystal L Mackall; W Marston Linehan; Josip Blonder
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

Review 9.  Improving the translation of analgesic drugs to the clinic: animal models of neuropathic pain.

Authors:  N Percie du Sert; A S C Rice
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

10.  Semi-mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain.

Authors:  A Taneja; I F Troconiz; M Danhof; O Della Pasqua
Journal:  Pharm Res       Date:  2013-10-05       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.